Back to search
FDAFDA · Food and drugs·Recall number D-0377-2021

Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial, Rx Only, TEVA Parenteral Medicines, Inc. Irvine, CA 92618 NDC 0703-4502-04

Published May 26, 2021 · Recall initiated: April 26, 2021

Summary

FDA records drug Class II recall D-0377-2021, published May 26, 2021 and initiated April 26, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 3,138/25 single use vials per tray; Lot: Lot # 31325459B, exp. date 08/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email if METOCLOPRAMIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
METOCLOPRAMIDE
Manufacturer
Teva Pharmaceuticals USA
Distributor
Product was distributed nationwide.
Lot
Lot # 31325459B, exp. date 08/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 2 mL Single-Use Vial, Rx Only, TEVA Parenteral Medicines, Inc. Irvine, CA 92618 NDC 0703-4502-04 recalled?

Yes. FDA published recall D-0377-2021 on May 26, 2021. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: METOCLOPRAMIDE.